SKINVIVE™ by JUVÉDERM®

PATIENT SAFETY INFORMATION

DIRECTIONS FOR USE

FOR PATIENTS

The first and only hyaluronic acid microdroplet injectable indicated to improve skin smoothness of the cheeks.

Lasting

Glow

CALL NOW

INDICATIONS SKINVIVE™ by JUVÉDERM® injectable gel is indicated for intradermal injection to improve facial skin smoothness of the cheeks in adults over the age of 21. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product. WARNINGS • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate --and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated --with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral schemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled • Injection site responses consist mainly of short-term inflammatory symptoms and generally resolve within 1 week. Refer to the ADVERSE EVENTS PRECAUTIONS • To minimize the risk of potential complications, this product should only be used by healthcare professionals who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection • Discuss all potential risks of soft tissue injections with patients prior to treatment and ensure patients are aware of signs and symptoms of potential complications • Limit patients to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs.) body mass per year. The safety of injecting greater amounts has not been established • This product is intended for improving skin smoothness and fine lines of the cheeks. The safety and effectiveness of use in other areas of the body have not been established • Injection of more than 6.0 mL of this product (initial and touch-up treatment combined) for improvement of skin smoothness and fine lines of the cheeks has not been studied • As with all transcutaneous procedures, injections of the product carry a risk of infection • The safety for use during pregnancy, in breastfeeding females, and in patients under 22 years has not been established • The safety in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied • This product should be used with caution in patients on immunosuppressive therapy • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti- inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites • Patients may experience late onset AEs with use of injectable gel implants, including this product • This product should only be used by healthcare professionals who have appropriate experience and who are knowledgeable about the anatomy and the product for use in the face • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site ADVERSE EVENTS In clinical studies, injection site responses (ISRs) observed in >5% of treated subjects included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most ISRs were mild. Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess. To report an adverse reaction with SKINVIVE™ by JUVÉDERM®, please call the Allergan® Product Support Department at 1-877-345-5372. Please see Directions for Use or visit SKINVIVEDFU.com for more information. SKINVIVE™ by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.

PRIVACY STATEMENT TERMS OF USE

© 2023 AbbVie. All rights reserved. JUVÉDERM, SKINVIVE and their designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are property of their respective owners. SKV155383 05/23

IMPORTANT SAFETY INFORMATION

MORE FROM ALLERGAN AESTHETICS

Lasts 6 months with optimal treatment. Glow was reported by patients using a validated scale that included satisfaction with how radiant their skin looked. Actual patients. Results may vary.

Thank you for your interest in SKINVIVE™ by JUVÉDERM

TRAINING

+ EXPAND INDICATIONS SKINVIVE™ by JUVÉDERM® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product.

Come back here for more information—our site is updating soon.

For US Healthcare Professionals

NOW AVAILABLE

*Lasts 6 months. As reported by patients in a composite satisfaction score, which includes how radiant their facial skin looked. Actual patient. Results may vary.

Thank you for your interest in SKINVIVE™ by JUVÉDERM®

This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). By clicking “Accept” you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above. You can still use this website if you do not click “Accept,” but your experience may be different. For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policy or for additional options please check your browser’s settings. Read Less

INDICATIONS SKINVIVE™ by JUVÉDERM® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product. WARNINGS • Do not inject into blood vessels. Introduction of this product into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral schemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled • Injection site responses consist mainly of short-term inflammatory symptoms and generally resolve within 1 week. Refer to the ADVERSE EVENTS PRECAUTIONS • To minimize the risk of potential complications, this product should only be used by healthcare professionals who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection • Discuss all potential risks of soft tissue injections with patients prior to treatment and ensure patients are aware of signs and symptoms of potential complications • Limit patients to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs.) body mass per year. The safety of injecting greater amounts has not been established • This product is intended for improving skin smoothness and fine lines of the cheeks. The safety and effectiveness of use in other areas of the body have not been established • Injection of more than 6.0 mL of this product (initial and touch-up treatment combined) for improvement of skin smoothness and fine lines of the cheeks has not been studied • As with all transcutaneous procedures, injections of the product carry a risk of infection • The safety for use during pregnancy, in breastfeeding females, and in patients under 22 years has not been established • The safety in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied • This product should be used with caution in patients on immunosuppressive therapy • Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites • Patients may experience late onset AEs with use of injectable gel implants, including this product • This product should only be used by healthcare professionals who have appropriate experience and who are knowledgeable about the anatomy and the product for use in the face • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site ADVERSE EVENTS In clinical studies, injection site responses (ISRs) observed in >5% of treated subjects included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most ISRs were mild. Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess. To report an adverse reaction with SKINVIVE™ by JUVÉDERM®, please call the Allergan® Product Support Department at 1-877-345-5372. Please see Directions for Use for more information. SKINVIVE™ by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.

Practice Resources

training

order now

Practice Resources

training

order now